Integrative Omics to Enhance Therapeutics Development for Healthy Aging (UH2/UH3 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) is a phased innovation initiative to facilitate multi-omics/integrative approaches to identify omics profiles associated with protection against multiple aging conditions, with exceptional health span, and to refine strategies for utilizing these profiles for therapeutics development. Specifically, a phased innovation cooperative agreement mechanism (UH2/UH3) involving an interdisciplinary research team will be used to support a single project that will conduct integrative analysis of person-specific multiple omics measurements (e.g., transcriptomics, proteomics, metabolomics) generated across multiple tissues; the multi-omic profiling should be conducted on individuals from extensively phenotyped cohorts with substantial numbers of long-lived individuals with characteristics of exceptionally healthy aging and appropriate controls. It will also: 1) harmonize and extend the use of existing phenotypic data from these studies to apply phenomics to transcriptomic, proteomic, metabolomic findings; 2) select animal model species or strains with varying life spans for comparative omics studies and identify potential determinants of species differences in longevity and rates of disease development; 3) develop appropriate computational and analytical tools to identify omics profiles associated with exceptional longevity and healthy aging; 4) apply translational bioinformatics approaches and leverage existing publicly available drug signatures databases to identify molecules that could produce profiles associated with exceptionally healthy aging; and 5) exchange data with other NIH/NIA-supported related omics activities and other public-private partnerships (e.g., Trans-Omics for Precision Medicine (TOPMed), Accelerating Medicines Partnership-Alzheimer’s Disease (AMP-AD)) for data harmonization and analysis.


  • Letter of Intent Due Date(s): October 14, 2018
  • Application Due Date(s): November 14, 2018​

RFA-AG-19-011 Expiration Date November 15, 2018


Agency Website



Amount Description

Application budgets should not exceed $3.3 million in direct costs.

Applicants may request a total project period of up to 5 years. The maximum project period is 2 years for the UH2 phase and 3 years for the UH3 phase.     

    Funding Type





    Engineering and Physical Sciences
    Medical - Basic Science
    Medical - Clinical Science
    Medical - Translational

    External Deadline

    November 14, 2018